Switch theme
Sign up to access all valuation multiples
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
2023
196
Last FY Revenue n/a
LTM EBITDA -$244M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Apogee Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$244M.
In the most recent fiscal year, Apogee Therapeutics achieved revenue of n/a and an EBITDA of -$217M.
Apogee Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Apogee Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$244M | XXX | -$217M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$240M | XXX | -$217M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$216M | XXX | -$182M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Apogee Therapeutics's stock price is $37.
Apogee Therapeutics has current market cap of $2.1B, and EV of $1.6B.
See Apogee Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $2.1B | XXX | XXX | XXX | XXX | $-3.75 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Apogee Therapeutics has market cap of $2.1B and EV of $1.6B.
Apogee Therapeutics's trades at n/a EV/Revenue multiple, and -7.5x EV/EBITDA.
Equity research analysts estimate Apogee Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Apogee Therapeutics has a P/E ratio of -9.9x.
See valuation multiples for Apogee Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -6.7x | XXX | -7.5x | XXX | XXX | XXX |
| EV/EBIT | -6.8x | XXX | -7.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.9x | XXX | -11.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -9.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialApogee Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Apogee Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Apogee Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Apogee Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apogee Therapeutics acquired XXX companies to date.
Last acquisition by Apogee Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Apogee Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Apogee Therapeutics founded? | Apogee Therapeutics was founded in 2023. |
| Where is Apogee Therapeutics headquartered? | Apogee Therapeutics is headquartered in United States of America. |
| How many employees does Apogee Therapeutics have? | As of today, Apogee Therapeutics has 196 employees. |
| Who is the CEO of Apogee Therapeutics? | Apogee Therapeutics's CEO is Dr. Michael Henderson, M.D.. |
| Is Apogee Therapeutics publicy listed? | Yes, Apogee Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Apogee Therapeutics? | Apogee Therapeutics trades under APGE ticker. |
| When did Apogee Therapeutics go public? | Apogee Therapeutics went public in 2023. |
| Who are competitors of Apogee Therapeutics? | Similar companies to Apogee Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Apogee Therapeutics? | Apogee Therapeutics's current market cap is $2.1B |
| Is Apogee Therapeutics profitable? | Yes, Apogee Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Apogee Therapeutics? | Apogee Therapeutics's last 12 months EBITDA is -$244M. |
| What is the current EV/EBITDA multiple of Apogee Therapeutics? | Current EBITDA multiple of Apogee Therapeutics is -6.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
